BLCO
What one share of Bausch & Lomb holds
Ophthalmic Goods
Bausch + Lomb Corporation (and its subsidiaries) (“Bausch + Lomb,” “we,” “us,” “our” or the “Company”) is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life.
Bausch & Lomb’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $14.99 |
|---|---|
| Profit | −$0.48 |
| Capex (buildings and equipment) | $0.90 |
| Free cash flow | $0.39 |
| Cash and investments | $1.03 |
| Debt | $14.22 |
| Book value | $17.86 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $9.75 | −$0.05 | $0.72 | $0.77 | — | $28.54 |
| 2021 | $10.76 | $0.52 | $0.55 | $1.94 | — | $26.65 |
| 2022 | $10.76 | $0.02 | $0.50 | $0.49 | — | $20.09 |
| 2023 | $11.83 | −$0.74 | $0.52 | −$0.56 | — | $19.52 |
| 2024 | $13.62 | −$0.90 | $0.83 | −$0.17 | — | $18.37 |
| 2025 | $14.42 | −$1.02 | $0.99 | −$0.19 | — | $18.20 |